Summary & Overview
Other Infectious and Parasitic Diseases Diagnoses with CC: Inpatient Reimbursement Overview
DRG 868 encompasses other infectious and parasitic diseases with a Complication or Comorbidity and captures cases requiring inpatient resources beyond routine care. It matters for inpatient reimbursement because the Complication or Comorbidity designation influences the Diagnosis-Related Group relative weight and Centers for Medicare & Medicaid Services payment.
DRG 868 Overview
DRG 868 covers hospital admissions for other infectious and parasitic diseases accompanied by a Complication or Comorbidity. This Diagnosis-Related Group groups patients whose infections require inpatient care but do not meet Major Complication or Comorbidity criteria, affecting average resource use and length of stay. It matters for Centers for Medicare & Medicaid Services inpatient payment because the presence of a Complication or Comorbidity adjusts relative weight and reimbursement compared with non-CC and Major Complication or Comorbidity categories. Accurate coding of infection diagnoses and associated Complication or Comorbidity is central to correct Medicare billing under this Diagnosis-Related Group.
Clinical Trials
- Acute antimicrobial strategy trials: randomized or pragmatic trials comparing different initial inpatient antimicrobial approaches (such as broad-spectrum combination versus targeted therapy guided by rapid diagnostic tests) for serious non-specific infectious and parasitic conditions with complicating comorbidities. These studies enroll hospitalized adults who present with sepsis-spectrum or severe focal infections that do not fall into other DRG categories and often have CC-level complications (e.g., immunosuppression, organ dysfunction). Results inform early-treatment algorithms, antimicrobial stewardship, and inpatient resource utilization metrics important to clinicians and payers because early appropriate therapy influences length of stay, complication rates, and downstream costs.
- Comparative effectiveness and diagnostic pathway studies: prospective cohorts or cluster-randomized trials evaluating different diagnostic workflows (rapid molecular diagnostics, imaging strategies, or biomarker-guided evaluation) and their impact on therapy selection and clinical outcomes for heterogeneous infectious/parasitic presentations grouped in this DRG. These studies focus on patients admitted with undifferentiated infections or parasitic diagnoses complicated by CCs, aiming to reduce diagnostic uncertainty, unnecessary broad-spectrum therapy, and delays to targeted treatment. Findings help hospitals and payers optimize care pathways, reduce avoidable testing or treatments, and improve coding and resource allocation for this catch-all DRG.
- Post-discharge outcomes and care-transition studies: observational or interventional studies assessing readmission, long-term functional outcomes, adherence to outpatient antimicrobial therapy, and coordination of care after discharge for patients with complex infectious/parasitic diagnoses and comorbid CCs. These investigations target the high-risk subgroup within this DRG—patients with multi-morbidity or needing prolonged IV antibiotics—evaluating interventions such as enhanced discharge planning, outpatient parenteral antimicrobial therapy (OPAT) programs, or remote monitoring. Results are directly relevant to providers and payers because reducing readmissions and optimizing post-acute care pathways can substantially affect total episode costs and quality metrics associated with inpatient stays coded to this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.